Canadian psychedelic biotech company Cybin announced the development of EMBARKCT, a streamlined version of its EMBARK Training Program.
EMBARKCT is a training program that enables Cybin to screen, qualify, train, and certify facilitators for larger clinical trials, providing support and in-person monitoring. The program focuses on future pivotal studies of Cybin's lead candidates, CYB003 and CYB004, which aim to treat major depressive disorder and generalized anxiety disorder, respectively.
The program builds upon the foundation laid by EMBARK Open Access (EMBARK OA), a free online training course for psychedelic facilitation. EMBARKCT is designed to scale up and improve accessibility to training resources, potentially increasing the number of facilitators participating in Cybin-sponsored clinical trials.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.